Last reviewed 2026-04-20 · How we verify

Androdiol (METHANDRIOL)

Phase 2 active Small molecule

Androdiol (generic name: METHANDRIOL) is a methandriol drug. It is currently in Phase 2 development.

Android works by binding to androgen receptors in the body, triggering a cascade of effects that mimic the action of male hormones.

Android (Methandriol) is a synthetic anabolic-androgenic steroid of the methandriol class. It is a small molecule that works by mimicking the effects of male hormones in the body, such as testosterone. Android is used to treat conditions associated with low testosterone levels, but its exact target and approved indications are unknown. The commercial status of Android is unclear, and it may be off-patent or have a complex patent situation. As a result, its availability and safety considerations are uncertain.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METHANDRIOL
Drug class	methandriol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body has locks on the doors of cells that only male hormones can open. Android is a key that fits into these locks, allowing the hormone-like effects to flow into the cell and stimulate growth and development.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Androdiol CI brief — competitive landscape report
Androdiol updates RSS · CI watch RSS

Frequently asked questions about Androdiol

What is Androdiol?

Androdiol (METHANDRIOL) is a methandriol drug.

How does Androdiol work?

Android works by binding to androgen receptors in the body, triggering a cascade of effects that mimic the action of male hormones.

What is the generic name of Androdiol?

METHANDRIOL is the generic (nonproprietary) name of Androdiol.

What drug class is Androdiol in?

Androdiol belongs to the methandriol class. See all methandriol drugs at /class/methandriol.

What development phase is Androdiol in?

Androdiol is in Phase 2.

Drug class: All methandriol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing